# NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)

Source: https://onco.cc/trials/nct06081244/  
OnCo record `nct06081244` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of sacituzumab govitecan and pembrolizumab in triple-negative breast cancer, run by Women's Cancer Study Group GmbH, now recruiting.

## Summary

NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III). ClinicalTrials.gov record last updated 2026-08-03: recruiting. Enrollment is planned at 348 participants. Primary completion is estimated at 2029-09. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Sacituzumab govitecan, Pembrolizumab. Registered primary measures: pathological complete remission (pCR); invasive disease-free survival rate (iDFS),.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Also known as: ADAPT-TN-III
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06081244
- Phase: 3
- Setting: NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
- Sponsor: Women's Cancer Study Group GmbH
- Enrolled: 348

## Notes

- ClinicalTrials.gov record last updated 2026-08-03: recruiting. Enrollment is planned at 348 participants. Primary completion is estimated at 2029-09. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.

## Sources

- ClinicalTrials.gov NCT06081244: https://clinicaltrials.gov/study/NCT06081244

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [TROP2](https://onco.cc/targets/trop2/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06081244.json